Sensei Biotherapeutics (NASDAQ:FTH) Coverage Initiated by Analysts at William Blair

Key Points

• William Blair initiated coverage of Sensei Biotherapeutics with an “outperform” rating, adding to broadly positive analyst sentiment. MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $56.25.
• Sensei Biotherapeutics shares opened at $20.60, with a market capitalization of approximately $532.3 million and a 12-month trading range of $7.45 to $42.14.
• Institutional investors have increased exposure to the company, including new positions from Vivo Capital, Stempoint Capital and Alyeska Investment Group; institutions collectively own 10.5% of the stock.

Research analysts at William Blair began coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set an "outperform" rating on the stock.

FTH has been the topic of several other reports. Weiss Ratings restated a "sell (d-)" rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. BTIG Research reaffirmed a "buy" rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a "buy" rating and a $56.00 price target for the company. JonesTrading initiated coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a "buy" rating and a $55.00 price target on the stock. Finally, Raymond James Financial started coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They set an "outperform" rating and a $56.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.25.

Sensei Biotherapeutics Trading Up 3.0%

FTH stock opened at $20.60 on Friday. The company's 50-day moving average is $31.50. The stock has a market cap of $532.30 million, a PE ratio of -0.15 and a beta of -0.29. Sensei Biotherapeutics has a twelve month low of $7.45 and a twelve month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($5.04) by $2.20. As a group, equities analysts forecast that Sensei Biotherapeutics will post -13.69 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the first quarter valued at about $22,758,000. Stempoint Capital LP bought a new position in Sensei Biotherapeutics during the first quarter valued at approximately $4,188,000. Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. Institutional investors own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company's approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients' responses to existing cancer treatments.

Sensei's pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.